Dexmedetomidine Dosing Evaluation for Sedation in Neonates Undergoing Therapeutic Hypothermia

OBJECTIVES: Recently, dexmedetomidine has replaced opioids for sedation in neonatal intensive care unit (NICU) patients with hypoxic-ischemic encephalopathy (HIE). The study objectives were to describe dosing patterns, evaluate compliance, and compare effectiveness and safety between the original (pre-implementation) and revised (post-implementation) in-house dexmedetomidine dosing guidelines. STUDY DESIGN: This was a retrospective cohort study that included neonates with HIE admitted to a level IV NICU for therapeutic hypothermia comparing two dexmedetomidine dosing regimens: (1) pre-implementation: starting dose of 0.05 μg/kg/h followed by titration by 0.05 μg/kg/h every 6 h as needed, and (2) post-implementation: 0.2 μg/kg/h followed by titration by 0.1 μg/kg/h every 30-60 min as needed. RESULTS: A total of 106 neonates were included: 50 in the pre-implementation group and 56 in the post-implementation group. Compliance to post-implementation formulary recommendations was 69.6% for initial doses, 62.5% for dose increases, and 44.6% for dose decreases. An increased odds of opioid exposure (adjusted odds ratio: 7.13, 95% confidence interval (CI): 1.59-51.5, p = 0.02) and greater proportion of bradycardia (21.4% vs. 4%, p = 0.03) were observed in the post-implementation group. No significant differences in effectiveness end points or hypotension were observed between groups (p ≥ 0.05). CONCLUSION: Compliance with formulary-recommended dexmedetomidine dosing was variable and dose decreases were common in the post-implementation group. The post-implementation dosing approach was not associated with improved effectiveness outcomes (sedation) but was associated with greater opioid exposure and more bradycardia, supporting the need for further prospective evaluation to determine the optimal dexmedetomidine dosing in neonates undergoing HIE.

Authors

Institutions

Publication Details

Journal
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
Published
2026-11-18
DOI
https://doi.org/10.1002/phar.70221
Primary Topic
Anesthesia and Sedative Agents
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Dexmedetomidine Dosing Evaluation for Sedation in Neonates Undergoing Therapeutic Hypothermia

Winnie Seto, Emily Tam, Erin Chung, Brian Thomas Kalish et al.
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
Anesthesia and Sedative Agents
article

Dexmedetomidine Dosing Evaluation for Sedation in Neonates Undergoing Therapeutic Hypothermia

Winnie Seto, Emily Tam, Erin Chung, Brian Thomas Kalish, Carol McNair, Han Byul Kang, Diane Wilson, Jennifer Bizzarri, Terrence Lo
article en

Abstract

OBJECTIVES: Recently, dexmedetomidine has replaced opioids for sedation in neonatal intensive care unit (NICU) patients with hypoxic-ischemic encephalopathy (HIE). The study objectives were to describe dosing patterns, evaluate compliance, and compare effectiveness and safety between the original (pre-implementation) and revised (post-implementation) in-house dexmedetomidine dosing guidelines. STUDY DESIGN: This was a retrospective cohort study that included neonates with HIE admitted to a level IV NICU for therapeutic hypothermia comparing two dexmedetomidine dosing regimens: (1) pre-implementation: starting dose of 0.05 μg/kg/h followed by titration by 0.05 μg/kg/h every 6 h as needed, and (2) post-implementation: 0.2 μg/kg/h followed by titration by 0.1 μg/kg/h every 30-60 min as needed. RESULTS: A total of 106 neonates were included: 50 in the pre-implementation group and 56 in the post-implementation group. Compliance to post-implementation formulary recommendations was 69.6% for initial doses, 62.5% for dose increases, and 44.6% for dose decreases. An increased odds of opioid exposure (adjusted odds ratio: 7.13, 95% confidence interval (CI): 1.59-51.5, p = 0.02) and greater proportion of bradycardia (21.4% vs. 4%, p = 0.03) were observed in the post-implementation group. No significant differences in effectiveness end points or hypotension were observed between groups (p ≥ 0.05). CONCLUSION: Compliance with formulary-recommended dexmedetomidine dosing was variable and dose decreases were common in the post-implementation group. The post-implementation dosing approach was not associated with improved effectiveness outcomes (sedation) but was associated with greater opioid exposure and more bradycardia, supporting the need for further prospective evaluation to determine the optimal dexmedetomidine dosing in neonates undergoing HIE.

Pharmacotherapy The Journal of Human Pharmacology and Drug TherapyVol. 46(12)
Boston Children's Hospital (US), University of Toronto (CA), Hospital for Sick Children (CA)
Anesthesia and Sedative Agents
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon